Authors
Loading...
Randomized trial characterizes SARS-CoV-2 interactions and microbial compositions in COVID-19 patients, suggesting new therapeutic targets.
Rjaibi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: